Full TitleA Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
The purpose of this study is to find the highest dose of the investigational drug LY3410738 that can be given safely in patients with metastatic solid tumors that contain mutations in the IDH1 gene. LY3410738 works by blocking the mutated IDH1 protein, which is believed to play an active role in cancer growth. LY3410738 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a metastatic solid tumor that contains an IDH1 R132 mutation and cannot be effectively treated with standard therapies.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. James Harding at 646-888-4314.